-
公开(公告)号:US11456485B2
公开(公告)日:2022-09-27
申请号:US16850121
申请日:2020-04-16
IPC分类号: H01M10/0568 , H01M10/0567 , H01M10/36 , H01G11/52 , H01G11/64 , H01G11/62 , C07C317/04 , C07C311/49
摘要: Disclosed is an electrochemical cell, which may be used for advanced rechargeable batteries. The electrochemical cell comprises two or more electrodes within an electrolyte solution, where the electrolyte solution containing (i) an aliphatic or cyclic sulfone and (ii) a metal perfluoroalkylsulfonylimide salt.
-
公开(公告)号:US20210238119A1
公开(公告)日:2021-08-05
申请号:US17228648
申请日:2021-04-12
IPC分类号: C07C50/28 , A61P39/06 , C07C50/24 , C07D295/108 , C07C317/04 , C07D207/06 , C07D213/65 , C07C225/24
摘要: Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.
-
公开(公告)号:US20210066754A1
公开(公告)日:2021-03-04
申请号:US16850121
申请日:2020-04-16
IPC分类号: H01M10/0568 , H01M10/0567 , H01M10/36 , H01G11/62 , H01G11/64 , H01G11/52 , C07C317/04 , C07C311/49
摘要: Disclosed is an electrochemical cell, which may be used for advanced rechargeable batteries. The electrochemical cell comprises two or more electrodes within an electrolyte solution, where the electrolyte solution containing (i) an aliphatic or cyclic sulfone and (ii) a metal perfluoroalkylsulfonylimide salt.
-
公开(公告)号:US20200377451A1
公开(公告)日:2020-12-03
申请号:US16995048
申请日:2020-08-17
发明人: Omer Refa Koseoglu , Robert Peter Hodgkins , Adnan Al-Hajji , Hendrik Muller , Nadrah Al-Awani , Frederick Marie Adam , Qasim Saleem
IPC分类号: C07C317/04 , C07C315/02 , C10G53/14
摘要: Oxidized disulfide oil (ODSO) solvent compositions are derived from by-product disulfide oil (DSO) compounds produced as by-products from the generalized mercaptan oxidation (MEROX) processing of a refinery feedstock. The oxidized disulfide oil (ODSO) solvent compositions comprise at least a primary oxidized disulfide oil (ODSO) compound selected from either water soluble or water insoluble oxidized disulfide oil (ODSO) compounds and in some embodiments at least 0.1 ppmw of a secondary oxidized disulfide oil (ODSO) compound that is a water soluble oxidized disulfide oil (ODSO) compound.
-
公开(公告)号:US20200331835A1
公开(公告)日:2020-10-22
申请号:US16946786
申请日:2020-07-06
IPC分类号: C07C50/28 , C07C50/24 , C07D207/06 , A61P39/06 , C07C225/24 , C07C317/04 , C07D213/65 , C07D295/108
摘要: Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.
-
公开(公告)号:US10781168B2
公开(公告)日:2020-09-22
申请号:US16210266
申请日:2018-12-05
发明人: Omer Refa Koseoglu , Robert Peter Hodgkins , Adnan Al-Hajji , Hendrik Muller , Nadrah Al-Awani , Frederick Marie Adam , Qasim Saleem
IPC分类号: C07C317/04 , C07C315/02 , C10G53/14 , C07C7/10 , C07C319/30 , C10G27/10
摘要: Oxidized disulfide oil (ODSO) solvent compositions are derived from by-product disulfide oil (DSO) compounds produced as by-products from the generalized mercaptan oxidation (MEROX) processing of a refinery feedstock. The oxidized disulfide oil (ODSO) solvent compositions comprise at least a primary oxidized disulfide oil (ODSO) compound selected from either water soluble or water insoluble oxidized disulfide oil (ODSO) compounds and in some embodiments at least 0.1 ppmw of a secondary oxidized disulfide oil (ODSO) compound that is a water soluble oxidized disulfide oil (ODSO) compound.
-
公开(公告)号:US10364223B2
公开(公告)日:2019-07-30
申请号:US15895056
申请日:2018-02-13
发明人: Tetsuya Tamura , Satoshi Igawa
IPC分类号: C09K9/02 , G09G3/38 , G02F1/153 , G02F1/155 , C07C317/04 , C07D213/06 , C07D213/22 , C07D401/14 , C07F9/6558 , G02F1/1503
摘要: Provided is an organic compound, which is represented by the general formula (1): in the general formula (1), R1 and R2 are each independently selected from the group consisting of an alkyl group having 1 or more and 20 or less carbon atoms, an aryl group, an aralkyl group, and a heteroaryl group, R3 and R4 are each independently selected from an alkyl group having 1 or more and 10 or less carbon atoms, and an alkoxy group having 1 or more and 10 or less carbon atoms, and A1− and A2− each independently represent a monovalent anion.
-
公开(公告)号:US20180299764A1
公开(公告)日:2018-10-18
申请号:US15882307
申请日:2018-01-29
申请人: HEE Solar, L.L.C.
IPC分类号: G03C8/36 , B05D3/10 , C01D3/12 , C01G21/16 , H01L51/00 , B05D1/38 , H01L51/42 , C07C19/00 , C07C233/03 , G03C1/035 , C07C317/04
摘要: A method for preparing photoactive perovskite materials. The method comprises the steps of: introducing a lead halide and a first solvent to a first vessel and contacting the lead halide with the first solvent to dissolve the lead halide to form a lead halide solution, introducing a Group 1 metal halide a second solvent into a second vessel and contacting the Group 1 metal halide with the second solvent to dissolve the Group 1 metal halide to form a Group 1 metal halide solution, and contacting the lead halide solution with the Group 1 metal halide solution to form a thin-film precursor ink. The method further comprises depositing the thin-film precursor ink onto a substrate, drying the thin-film precursor ink to form a thin film, annealing the thin film; and rinsing the thin film with a salt solution.
-
公开(公告)号:US20180065942A1
公开(公告)日:2018-03-08
申请号:US15812524
申请日:2017-11-14
申请人: ADVERIO PHARMA GMBH
发明人: Peter FEY , Alfons GRUNENBERG , Donald BIERER
IPC分类号: C07D295/104 , C07D295/067 , C07C317/04 , C07C309/04 , C07D265/30 , C07D471/04 , C07C303/28 , C07C309/65
CPC分类号: C07D295/104 , A61P9/00 , C07B2200/13 , C07C303/28 , C07C309/04 , C07C317/04 , C07D265/30 , C07D295/067 , C07D471/04 , C07C309/65
摘要: The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
-
10.
公开(公告)号:US20170362182A1
公开(公告)日:2017-12-21
申请号:US15639223
申请日:2017-06-30
IPC分类号: C07D223/26 , A61K9/16 , C07D213/82 , C07D213/79 , C07D213/69 , C07D213/22 , C07D213/06 , C07C317/04 , C07C233/75 , C07C233/25 , C07C233/03 , C07C205/57 , C07C69/157 , C07C63/307 , C07C61/135 , C07C57/58 , C07C57/30 , C07C53/124 , C07C53/08 , C07C53/02 , C07C51/43 , C07C51/41 , C07C47/544 , A61K47/32 , A61K47/10 , A61K31/616 , A61K31/55 , A61K31/4166 , A61K31/192 , A61K31/167 , C07D233/74 , C07D275/06
CPC分类号: C07D223/26 , A61K9/1652 , A61K31/167 , A61K31/192 , A61K31/4166 , A61K31/55 , A61K31/616 , A61K47/10 , A61K47/32 , C07C47/544 , C07C51/412 , C07C51/43 , C07C53/02 , C07C53/08 , C07C53/124 , C07C57/30 , C07C57/58 , C07C61/135 , C07C63/307 , C07C69/157 , C07C205/57 , C07C233/03 , C07C233/25 , C07C233/75 , C07C317/04 , C07D213/06 , C07D213/22 , C07D213/69 , C07D213/79 , C07D213/82 , C07D233/74 , C07D275/06 , C07C53/06 , C07C53/10
摘要: The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.
-
-
-
-
-
-
-
-
-